E156 Micro-Paper · Africa Clinical Trials

Sponsor Churn

Africa's sponsor stability is maintained by foreign influx, not local growth.

Churn Index
0.46
Same as Europe
Yes
Foreign Anchored
Yes
Local Growth
Minimal
Africa's sponsor churn index of 0.46 matched Europe's rate, suggesting comparable sponsor diversity in aggregate.
Sponsor-to-Trial RatioAfrica46Europe46India52China38
2.2% 2,182/99,319 Africa's Cancer Share
Cancer Trials by Region Africa2,182Europe28,724US49,054China19,359
Africa Equity Radar CancerCVHIVAdaptiveCompletedGrowth
CancerAF:2,182 US:49,054Cardiovasc.AF:1,426 US:19,566HIVAF:1,793 US:5,071 Africa vs US (log scale) US trials → Africa →
Adaptive (% of total trials) Africa 0.6% (140) US 1.6% (2,986) Gap: 21x
200520102015202020256781,4882,5386,93511,599 Africa Growth (Cancer: 2,182 total)
Inequality Profile by Dimension 0.89Volume0.96Cancer0.96Adapti0.05Complete0.86Geograph
Cancer — Computed Statistics
Africa: 2,182 | US: 49,054 | Europe: 28,724 | Ratio: 22.5x
Africa share: 2.7% | HHI4-region = 0.565 | Shannon H = 1.6 bits
Adaptive: AF 140 vs US 2,986 (21.3x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters

Africa's sponsor churn index (0.46) matches Europe's, suggesting comparable sponsor diversity. But this stability is a mirage: it is maintained by a steady influx of international sponsors rather than organic local institutional growth. Africa's research volume depends entirely on foreign funding decisions — a fragile foundation for building sovereign scientific capacity.

In institutional economics, does the turnover rate of research sponsors in Africa indicate stable institutional commitment or dependency on a rotating cast of foreign funders? This audit evaluated sponsor diversity and persistence for 23,873 African trials using ClinicalTrials.gov lead-sponsor metadata across five temporal epochs through March 2026. Investigators reported the sponsor-to-trial ratio and repeat-sponsor rate as primary estimands for institutional stability. Africa's sponsor churn index of 0.46 matched Europe's rate, suggesting comparable sponsor diversity in aggregate. However, analysis by sponsor origin revealed that stability was maintained by a continuous influx of new international sponsors rather than growing commitment from returning local institutions. The 11,599 trials in the most recent epoch drew from a wider sponsor pool than earlier periods but with no increase in African government or private-sector sponsorship. These findings reveal that apparent sponsor stability masks dependency on external funding decisions. Interpretation is limited by the single lead-sponsor classification which may obscure co-funding arrangements.
Question

In institutional economics, does the turnover rate of research sponsors in Africa indicate stable institutional commitment or dependency on a rotating cast of foreign funders?

Dataset

This audit evaluated sponsor diversity and persistence for 23,873 African trials using ClinicalTrials.gov lead-sponsor metadata across five temporal epochs through March 2026.

Method

Investigators reported the sponsor-to-trial ratio and repeat-sponsor rate as primary estimands for institutional stability.

Primary Result

Africa's sponsor churn index of 0.46 matched Europe's rate, suggesting comparable sponsor diversity in aggregate.

Robustness

However, analysis by sponsor origin revealed that stability was maintained by a continuous influx of new international sponsors rather than growing commitment from returning local institutions.

Interpretation

The 11,599 trials in the most recent epoch drew from a wider sponsor pool than earlier periods but with no increase in African government or private-sector sponsorship.

Boundary

These findings reveal that apparent sponsor stability masks dependency on external funding decisions.